Brief: Synact Pharma Improves Design Of Ongoing Phase 2A Study In iMN

SynAct Pharma AB

21/07/2022 06:06

July 21 (Reuters) - SynAct Pharma AB  SYNACT.ST :
    * SYNACT PHARMA IMPROVES THE DESIGN OF THE ONGOING PHASE 2A
STUDY
IN IMN
    * HAS APPLIED FOR APPROVAL OF A MAJOR AMENDMENT OF ONGOING
SYNACT-CS003 STUDY WITH COMPANY'S CANDIDATE DRUG AP1189 IN
IDIOPATHIC MEMBRANOUS NEPHROPATHY (IMN) PATIENTS WITH SEVERE
PROTEINURIA AND/OR NEPHROTIC SYNDROME (NS)

Source text for Eikon:  ID:nMFN6jg4Jx 
Further company coverage:  SYNACT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))